Close menu




May 5th, 2022 | 11:52 CEST

Biotech-Investments also work conservatively: BioNTech, XPhyto, Valneva

  • Biotechnology
  • Pharma
  • Covid19
Photo credits: pixabay.com

Biotech stocks are often seen as all-or-nothing investments - either a bet works out, or the companies disappear into oblivion. But innovative companies in the pharmaceutical and biotech sectors do not always operate in just one area. They are not always spectacular projects that are dependent on approval procedures. We outline the investment opportunities around three well-known biotech stocks.

time to read: 3 minutes | Author: Nico Popp
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , XPHYTO THERAPEUTICS | CA98421R1055 , VALNEVA SE EO -_15 | FR0004056851

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    BioNTech: Much ahead, much behind

    BioNTech's stock is clearly a Corona beneficiary. The manufacturer was the pioneer apart from Russia's Sputnik V vaccine and is still the top choice alongside Moderna when it comes to COVID-19 vaccines. But what else does BioNTech have to offer? Thanks to its flexible mRNA technology, the Mainz-based company has a wide range of options. At the end of last year, BioNTech announced a commitment to vaccines against influenza, tuberculosis, HIV and malaria. BioNTech is also repeatedly associated with the fight against cancer.

    After BioNTech's share price more than halved since the vaccine announcements in December, investors can focus on the share once again. The value seems to have stabilized above EUR 100. Since the pandemic does not seem to be over yet and new rounds of vaccination are becoming more and more likely, the wheels should continue to roll at BioNTech. The Company remains well-positioned and has a real cash cow in its portfolio with the covid vaccine.

    XPhyto: Hopeful biosensors

    The up-and-coming Canadian biotech company XPhyto has so far lacked a cash cow. However, the Canadians with good contacts in Germany are well-positioned in some niches. In particular, the biosensor business, which XPhyto uses to detect oral diseases such as periodontitis, peri-implantitis and stomatitis, in addition to covid infections, influenza and scarlet fever, could offer opportunities in the future. Just a few months ago, XPhyto acquired 3a-diagnostics GmbH, with which it had already cooperated, in its entirety. The goal at the time was to leverage synergies, create growth and commercialize the biosensors as quickly as possible. Five months after the takeover of 3a-diagnostics GmbH, investors can look forward to initial successes.

    In addition to the biosensor business, XPhyto also focuses on alternative dosage forms, such as patches or thin films that are placed under the tongue. With the help of innovative dosage forms, certain active ingredients can be used more effectively and thus at a lower cost. Especially around generics, where business is driven almost exclusively by price, cost advantages can quickly mean more market share. In addition to the two rather conservative pillars of biosensors and innovative dosage forms, XPhyto also offers research on psychedelic substances. This approach is socially acceptable, especially in North America, and is said to help treat depression, among other things. The XPhyto share has been languishing below the EUR 1 mark for months. If the rather down-to-earth business takes off, this could lead to a revaluation.

    Valneva: Hope thanks to Lyme disease vaccine

    The Valneva share shows that it can make sense to stand on several legs. Long hailed as a COVID-19 alternative, the Company recently suffered a setback in connection with the approval of the pandemic vaccine. By contrast, there was good news in connection with the planned Lyme disease vaccine. Especially now, in the summertime, the topic is coming back into focus. Lyme disease is transmitted by ticks and, along with meningococci, against which there is already a vaccine, is considered the more harmless consequence of tick bites. The disease can usually be treated well with antibiotics. The tricky thing is that Lyme disease symptoms vary and are often not recognized. So a vaccine would be beneficial and could effectively prevent complications around the nervous system, joints or even the heart that often accompany Lyme disease. Valneva's stock is currently at a crossroads. The value is still in an upward trend. Below EUR 10, however, the air is getting thin...


    Biotech companies do well to have several irons in the fire. While the development of drugs or vaccines is lengthy, expensive and risky, the bread-and-butter business around pharma and biotech also offers opportunities. XPhyto is well positioned around biosensors and alternative dosage forms and aims to be marketable in 2022. If it succeeds, the stock will stand in a new light.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Juliane Zielonka on April 12th, 2024 | 07:00 CEST

    AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

    • Biotechnology
    • Pharma
    • AI

    Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?

    Read

    Commented by Fabian Lorenz on April 10th, 2024 | 07:00 CEST

    BASF and Cardiol Therapeutics recommended to buy! TUI share with momentum!

    • Biotechnology
    • Cancer
    • travel
    • chemicals

    BASF shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the share did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see little potential for further price increases. The situation is different for the biotech company Cardiol Therapeutics. The analysts at Canaccord believe that the shares of the specialist in cardiovascular diseases could perform by around 200%. Financing is secured until 2026, and important study data is due in the current quarter. The TUI share has been on a roll for several months now. Will the share continue to rise with the increase in temperatures? Management is certainly optimistic about the future.

    Read

    Commented by André Will-Laudien on April 10th, 2024 | 06:45 CEST

    Attention: Biotech takeovers, after MorphoSys, now Bayer, Vidac Pharma, BioNTech and Pfizer are on the radar

    • Pharma
    • Biotechnology
    • Innovations

    Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the cancer specialist from Munich. Only months before, MorphoSys had been traded on the stock exchange at just EUR 700 million. The special market situation in this case was also characterized by the high short ratio, which led to an exorbitant rise in the share price of almost 400% in the final phase. Speculative investors are now keeping a wary eye on potential takeover candidates as the sector is once again attracting considerable attention. We are taking a closer look and searching for the next pearl.

    Read